General Information of Drug (ID: DMJAPFH)

Drug Name
Asterric acid Drug Info
Synonyms
577-64-0; MLS000863583; CHEMBL469424; SMR000440714; 2-hydroxy-6-(4-hydroxy-2-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoic acid; AC1MIV9I; Asterric acid_120092; MEGxm0_000244; ZINC7778; SCHEMBL6046569; XOKVHFNTYHPEHN-UHFFFAOYSA-; cid_3080568; ACon1_001529; ACon0_000930; CTK8F7847; BDBM50711; DTXSID60206405; MolPort-001-739-484; HMS2270H17; MFCD00216131; MCULE-7550426133; NCGC00180411-01; Asterric acid, > L007432; BRD-K20637966-001-01-0
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3080568
CAS Number
CAS 577-64-0
TTD Drug ID
DMJAPFH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [2]
Ambrisentan DMD1QXW Pulmonary arterial hypertension BB01.0 Approved [3]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [4]
Sparsentan DMMP51W IgA nephropathy MF8Y Approved [5]
LU302146 DMMJVXZ Pulmonary hypertension BB01 Approved [6]
Atrasentan DMM74PK Diabetic nephropathy GB61.Z Phase 3 [7]
Clazosentan DMQSBX4 Cerebral vasospasm BA85.Z Phase 3 [8]
PF-1228305 DMS1EQ7 Pulmonary hypertension BB01 Phase 3 [9]
Darusentan DMN8DQH Hypotension BA20-BA21 Phase 3 [10]
BQ-123 DM0MO8I Pulmonary arterial hypertension BB01.0 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin A receptor (EDNRA) TTKRD0G EDNRA_HUMAN Inhibitor [1]

References

1 New chlorinated diphenyl ethers from an Aspergillus species. J Nat Prod. 2002 Jan;65(1):7-10.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
5 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
6 Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
7 Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
8 Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
9 Pfizer. Product Development Pipeline. March 31 2009.
10 Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
11 Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.